Journal of Rheumatology最新文献

{"title":"Tradition versus Innovation: Conventional Radiography and Ultrasound in Calcium Pyrophosphate Deposition Identification - Instructions for Use.","authors":"Georgios Filippou, Silvia Sirotti, Luca Maria Sconfienza, Lene Terslev, Anna Zanetti, Davide Rozza, Esperanza Naredo, Ulrike Novo-Rivas, Pascal Zufferey, Carlos Pineda, Marwin Gutierrez, Antonella Adinolfi, Teodora Serban, Daryl MacCarter, Gael Mouterde, Annamaria Iagnocco, Anna Scanu, Ingrid Möller, Abhishek Abhishek, Nicola Dalbeth, Sara Tedeschi, Tristan Pascart, Maria-Antonietta D'Agostino, Fabio Becce","doi":"10.3899/jrheum.2024-1339","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1339","url":null,"abstract":"<p><strong>Objective: </strong>Conventional radiography (CR) and ultrasound (US) are interchangeably used for identification of calcium pyrophosphate deposition (CPPD). The aim of this study was to assess whether combining US and CR offers greater accuracy over either modality alone for the identification of CPPD.</p><p><strong>Methods: </strong>Consecutive patients scheduled for knee replacement surgery for osteoarthritis were enrolled. Before surgery, patients underwent CR and US of the knee. Menisci and hyaline cartilage were collected and analysed using polarised light microscopy to confirm the presence of CPPD (gold standard). CR and US were assessed for absence/presence of CPPD by expert radiologists and sonographers. Diagnostic performance statistics were calculated. Poisson models with robust variance estimators were used to determine the likelihood of identifying CPPD.</p><p><strong>Results: </strong>51 patients (63% female, mean age 74 years ± 8 SD) were enrolled. US demonstrated higher overall accuracy than CR for CPPD identification (0.78 vs 0.73). Sequential use of both modalities provided an advantage when only one knee site was positive in one of the two techniques; however, when two or three sites were positive, no additional advantage was observed. When US was negative, subsequent CR did not improve CPPD detection, but in cases of a negative CR, a positive US increased the likelihood of CPPD by 4.21 times, while a negative US increased the likelihood of absence of CPPD by 76%.</p><p><strong>Conclusion: </strong>US was more accurate than CR for identification of CPPD. Only in few specific cases, performing both exams could be an added value for CPPD identification.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-Based Cohort (1998-2019).","authors":"Caitrin M Coffey, Cassondra A Hulshizer, Cynthia S Crowson, Jay H Ryu, Floranne C Ernste","doi":"10.3899/jrheum.2024-0945.C1","DOIUrl":"10.3899/jrheum.2024-0945.C1","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"627"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Genetic Studies on Rheumatic Diseases in Latin America: The IARGE-RD Initiative.","authors":"Josefina Durán, Bernardo A Pons-Estel, Marta E Alarcón-Riquelme, Roberto Díaz Peña","doi":"10.3899/jrheum.2024-1233","DOIUrl":"10.3899/jrheum.2024-1233","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"614-617"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding Fatigue and Sleep Disturbance in Polymyalgia Rheumatica: Redefining the Patient Experience and Opportunities for Intervention.","authors":"Patricia Harkins, Sebastian E Sattui","doi":"10.3899/jrheum.2025-0524","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0524","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between Interferon Response Gene Score and Disease Activity in Juvenile Dermatomyositis.","authors":"Jayne M MacMahon, Mohammad Massumi, Trang T Duong, Rose H Garrett, Audrey Bell-Peter, Kristi Whitney, Jo-Anne Marcuz, Y Ingrid Goh, Rae S M Yeung, Brian M Feldman","doi":"10.3899/jrheum.2024-0806","DOIUrl":"10.3899/jrheum.2024-0806","url":null,"abstract":"<p><strong>Objective: </strong>Type 1 interferons (IFNs) have been identified as potentially important measures of disease activity in juvenile dermatomyositis (JDM). An IFN response gene (IRG) score has been defined using NanoString technology and appears to correlate with disease activity in cross-sectional samples of patients with JDM. This study aimed to determine if there is evidence of a correlation between disease activity and IRG score in patients with JDM, both early in the disease course and longitudinally.</p><p><strong>Methods: </strong>All patients attending the JDM clinic at The Hospital for Sick Children (SickKids), in Toronto, Canada, were approached to enroll in the Childhood Arthritis and Rheumatic Diseases (CARD) biobank. We identified patients with a diagnosis of JDM, enrolled between January 2015 and June 2022. NanoString IRG score was calculated from extracted RNA. The modified Disease Activity Score was calculated based on clinical data collected prospectively through SickKids's JDM registry. Spearman correlation was calculated using all enrollment visit samples, and linear mixed model regression was used for subjects with multiple samples.</p><p><strong>Results: </strong>Forty-three subjects with 87 biosamples were identified, including 18 treatment-naïve subjects. Spearman correlation at the enrollment visit was strong (<i>r_s</i> 0.78) with similar results seen in the treatment-naïve cohort (<i>r_s</i> 0.63). This relationship persisted over time, with linear mixed modeling of the treatment-naïve cohort showing β coefficient for the IRG score of 0.004 with <i>P</i> < 0.001.</p><p><strong>Conclusion: </strong>This study shows evidence of a significant correlation between IRG score and disease activity, which is maintained over time. This highlights the potential for IRG score to be an important biomarker in JDM.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"604-612"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Varicella Zoster Virus Vaccination in Patients With Immune-Mediated Inflammatory Diseases: Drivers and Barriers.","authors":"Tiphaine Goulenok, Maria Carvalho, Arthur Mageau, Benjamin Terrier, Eric Hachulla, Thomas Papo, Karim Sacré","doi":"10.3899/jrheum.2025-0016","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0016","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HLA-B27 Testing in Clinical Practice: A Retrospective Analysis of Testing Indications and Rheumatology Referral Patterns.","authors":"Gregory C McDermott, Mathieu Choufani, Armaan Monshizadeh, Joerg Ermann","doi":"10.3899/jrheum.2025-0167","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0167","url":null,"abstract":"<p><strong>Objective: </strong>The human leukocyte antigen B27 (HLA-B27) allele is strongly associated with spondyloarthritis (SpA). HLA-B27 is included in SpA classification criteria and referral strategies for axial SpA. Investigations of HLA-B27 testing in usual clinical practice are limited.</p><p><strong>Methods: </strong>We identified all adult patients tested for HLA-B27 from 1/1/2022 to 12/31/2022 in the Mass General Brigham healthcare system. We examined patient demographics, ordering provider specialty, testing indication, concurrent testing with antinuclear antibodies, rheumatoid factor, or anti-cyclic citrullinated peptide autoantibodies, and rheumatology referral. We compared the rate of rheumatology referral between HLA-B27 positive and negative patients.</p><p><strong>Results: </strong>HLA-B27 tests were ordered for 1960 patients (62.4% female, average age 47.4 years). The most common specialties testing HLA-B27 were rheumatology (39.7%) and ophthalmology (21.4%). The most common indications for HLA-B27 testing were peripheral arthritis (33.0%), uveitis (22.0%), and back pain (16.7%). The majority of HLA-B27 tests (69.3%) were ordered concurrently with other autoantibody tests. A total of 10.9% of HLA-B27 tests were positive. Ophthalmology had the highest positive rate (15.4%) while reactive arthritis was the indication with the highest positive test rate (50%). A greater proportion of HLA-B27 positive patients were referred to rheumatology (53% vs 32%, p=0.002).</p><p><strong>Conclusion: </strong>HLA-B27 testing was frequently performed by rheumatologists and nonrheumatologists for a broad spectrum of indications. Co-testing HLA-B27 with ANA and rheumatoid arthritis autoantibodies was common. Nearly half of HLA-B27 positive patients were not referred to rheumatology. Further efforts are needed to promote judicious use of HLA-B27 testing and optimize referral pathways to rheumatology.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network.","authors":"Marion Pons, Stylianos Georgiadis, Merete Lund Hetland, Zohra Faizy Ahmadzay, Simon Rasmussen, Sara N Christiansen, Daniela Di Giuseppe, Johan K Wallman, Karel Pavelka, Jakub Závada, Catalin Codreanu, Bente Glintborg, Anne G Loft, Helena Santos, Maria H Lourenço, Michael J Nissen, Adrian Ciurea, Laura Kuusalo, Vappu Rantalaiho, Brigitte Michelsen, Pawel Mielnik, Katja P Pirkmajer, Ziga Rotar, Bjorn Gudbjornsson, Olafur Palsson, Irene van der Horst-Bruinsma, Marleen van de Sande, Isabel Castrejón, Gary J Macfarlane, Karin Laas, Mikkel Østergaard, Lykke M Ørnbjerg","doi":"10.3899/jrheum.2024-0920","DOIUrl":"10.3899/jrheum.2024-0920","url":null,"abstract":"<p><strong>Objective: </strong>In patients with axial spondyloarthritis (axSpA) initiating secukinumab (SEC), we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by the Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), as well as treatment continuation after 12 months.</p><p><strong>Methods: </strong>From 11 European registries, patients with axSpA who initiated SEC treatment in routine care, with available data on 6-month ASDAS-CRP and BASDAI assessments were included. Logistic regression analyses on multiply imputed baseline data were performed; potential baseline predictors included demographic, diagnosis, lifestyle, clinical, and patient-reported variables.</p><p><strong>Results: </strong>In a pooled cohort of 1174 patients with axSpA, 5 of 19 potential assessed variables were mutually predictive for achieving LDA by ASDAS-CRP and BASDAI: higher physician global assessment score, noncurrent smoking, lack of prior exposure to biologic/targeted synthetic disease-modifying antirheumatic drugs, and lower Health Assessment Questionnaire scores and BASDAI scores. Moreover, radiographic axSpA and CRP ≤ 10 mg/L were associated with achieving ASDAS-CRP LDA, and HLA-B27 positivity and history of psoriasis with achieving BASDAI LDA, whereas earlier time of secukinumab initiation (2015-2017) was associated with treatment continuation.</p><p><strong>Conclusion: </strong>In this European real-world study of patients with axSpA initiating SEC, predictors of achieving LDA by ASDAS-CRP and BASDAI at 6 months and remaining on treatment at 12 months included both clinical, patient-reported, and lifestyle factors, underscoring the complex mechanisms of real-world drug effectiveness.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"572-582"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Mortality of People With Psoriasis and Psoriatic Arthritis in Taiwan: A Nationwide Cohort Study.","authors":"Charmaine Tze May Wang, Jing-Yang Huang, Pei-Lun Liao, James Cheng-Chung Wei, Ying Ying Leung","doi":"10.3899/jrheum.2024-1032","DOIUrl":"10.3899/jrheum.2024-1032","url":null,"abstract":"<p><strong>Objective: </strong>Residual confounding effects and disease severity are attributed to controversial results in studies of psoriatic disease (PsD) and mortality. We aimed to evaluate the risk of mortality in patients with incident PsD, compared to matched controls from the population.</p><p><strong>Methods: </strong>We used the nationwide, population-based insurance claim datasets in Taiwan from 2010 to 2018. Incident cases of PsD were identified by International Classification of Diseases (ICD) codes. A nonexposed cohort was established through propensity score matching (PSM). Deaths were identified via the National Mortality Database. We evaluated the risk of all-cause mortality in PsD compared to the PSM nonexposed individuals using Cox regression. The mortality risk was evaluated in patients with more severe disease stratified by systemic therapy use and having psoriatic arthritis (PsA).</p><p><strong>Results: </strong>There were 108,642 patients with incident PsD (40.2% women) and an equal number of PSM non-PsD individuals. Compared to the age- and sex-matched controls, there was a higher risk of mortality among patients with PsD (adjusted hazard ratio [aHR] 1.73, 95% CI 1.68-1.77, <i>P</i> < 0.001). After PSM, we found an attenuated but persistent higher risk of mortality in PsD compared to controls (aHR 1.20, 95% CI 1.16-1.24). There was a trend of higher mortality in patients exposed to biologic therapies, but not for PsA.</p><p><strong>Conclusion: </strong>There was an increased risk of all-cause mortality in individuals with PsD compared to individuals without PsD before and after both PSM and adjustment for comorbidities. The risk of mortality was higher in patients with psoriasis but not in patients with PsA as compared to controls.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"590-597"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Differences in Rheumatoid Arthritis: New Insights From Clinical and Patient-Reported Outcome Perspectives.","authors":"Gonul Hazal Koc, Agnes E M Looijen, Irene E van der Horst-Bruinsma, Pascal H P de Jong","doi":"10.3899/jrheum.2024-1258","DOIUrl":"10.3899/jrheum.2024-1258","url":null,"abstract":"<p><strong>Objective: </strong>The disease course and burden of rheumatoid arthritis (RA) may differ between female and male individuals, but existing data on these differences are limited and often contradictory. Therefore, we investigated whether clinical outcomes and patient-reported outcomes (PROs) differ between female and male patients with RA over time.</p><p><strong>Methods: </strong>All female (n = 286) and male (n = 139) patients with RA according to 1987 and/or 2010 criteria from Treatment in the Rotterdam Early Arthritis Cohort (tREACH), a stratified single-blinded trial with a treat-to-target (T2T) approach and fixed medication protocol, were included. Clinical outcomes include disease activity, medication usage, sustained disease-modifying antirheumatic drug (DMARD)-free remission (SDFR), and radiographic progression. In addition, the following PROs were investigated: general health, pain, functional ability, health-related quality of life, fatigue, productivity loss, and a possible depression or anxiety disorder. For comparisons over time, a mixed model or Cox proportional hazard model was used. The mixed models were adjusted for age, initial treatment, and disease activity (Disease Activity Score in 44 joints [DAS44]).</p><p><strong>Results: </strong>Female patients had a higher DAS44 over time compared to male patients (β 0.36, 95% CI 0.25-0.47, <i>P</i> < 0.001), which also resulted in more treatment adjustments including use of biologic DMARDs (bDMARDs; 36% vs 24%, <i>P</i> < 0.001). Although not significant, first bDMARD survival seemed shorter in female patients (hazard ratio [HR] 1.4, 95% CI 0.8-2.6, <i>P</i> = 0.24). However, no differences were found in SDFR and radiographic progression. With regard to PROs, only functional ability differed significantly between sexes after adjusting for confounders, including disease activity (Health Assessment Questionnaire-Disability Index, β 0.10, 95% CI 0.04-0.17, <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Clinical outcomes and PROs are intertwined, and both improve with a T2T management approach. Nevertheless, female patients with RA have higher disease activity, a greater need for bDMARDs-although these have lower efficacy-and more functional impairment over time, underscoring the need for sex-specific management recommendations. (Trial registration number: ISRCTN26791028).</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"553-562"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}